story of the week
HRQOL in Patients With Relapsed/Refractory Multiple Myeloma Receiving Ciltacabtagene Autoleucel Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study
Lancet Haematol 2022 Oct 07;[EPub Ahead of Print], T Martin, Y Lin, M Agha, AD Cohen, M Htut, AK Stewart, P Hari, JG Berdeja, SZ Usmani, TM Yeh, Y Olyslager, JD Goldberg, JM Schecter, D Madduri, CC Jackson, W Deraedt, KS Gries, JM Fastenau, JJ Trudeau, M Akram, L Pacaud, A Jakubowiak, S JagannathFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.